X-LINKED RETINITIS PIGMENTOSA
Clinical trials for X-LINKED RETINITIS PIGMENTOSA explained in plain language.
Never miss a new study
Get alerted when new X-LINKED RETINITIS PIGMENTOSA trials appear
Sign up with your email to follow new studies for X-LINKED RETINITIS PIGMENTOSA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy hope for rare blindness: phase 3 Follow-Up underway
Disease control OngoingThis study follows 97 people with X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss, after they received a gene therapy called AAV5-hRKp.RPGR. Researchers are checking for side effects and measuring changes in eyesight over time. The goal is to see if t…
Matched conditions: X-LINKED RETINITIS PIGMENTOSA
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 17, 2026 11:39 UTC
-
Gene therapy offers hope for boys and men losing sight to rare eye disease
Disease control OngoingThis study tests a gene therapy called AGTC-501 in males aged 12 to 50 with X-linked retinitis pigmentosa, a genetic eye disease that slowly destroys vision. The treatment aims to improve low-light eyesight by delivering a working copy of the faulty RPGR gene. About 85 participan…
Matched conditions: X-LINKED RETINITIS PIGMENTOSA
Phase: PHASE2, PHASE3 • Sponsor: Beacon Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Second-Eye gene therapy trial offers hope for rare vision loss
Disease control OngoingThis study tests a gene therapy given to the second eye of people with X-linked retinitis pigmentosa, a genetic condition that causes vision loss. About 24 adults and children who already received treatment in one eye will get the therapy in their other eye. Researchers will chec…
Matched conditions: X-LINKED RETINITIS PIGMENTOSA
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 15, 2026 11:53 UTC